SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-083403
Filing Date
2024-04-01
Accepted
2024-04-01 16:18:01
Documents
16
Period of Report
2024-03-31
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.03: Bankruptcy or Receivership
Item 2.04: Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d818699d8k.htm   iXBRL 8-K 43226
2 EX-10.1 d818699dex101.htm EX-10.1 318457
3 EX-99.1 d818699dex991.htm EX-99.1 7935
7 GRAPHIC g818699g0401191418204.jpg GRAPHIC 8418
  Complete submission text file 0001193125-24-083403.txt   590384

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA eigr-20240331.xsd EX-101.SCH 2853
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE eigr-20240331_lab.xml EX-101.LAB 18757
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE eigr-20240331_pre.xml EX-101.PRE 11712
19 EXTRACTED XBRL INSTANCE DOCUMENT d818699d8k_htm.xml XML 3779
Mailing Address 2155 PARK BOULEVARD PALO ALTO CA 94306
Business Address 2155 PARK BOULEVARD PALO ALTO CA 94306 650-279-9845
Eiger BioPharmaceuticals, Inc. (Filer) CIK: 0001305253 (see all company filings)

IRS No.: 361004130 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36183 | Film No.: 24809540
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)